Idiopathic pulmonary fibrosis (IPF) is a difficult to treat condition to treat with a high mortality rate. While preclinical models such as Bleomycin (Bleo)-induced fibrosis recapitulate some aspects of IPF, new models that more closely mimic the disease are warranted. We have developed and characterized a novel model in BALB/c mice using a transient overexpression of IL-6 combined with Bleo. This model’s transcriptomic signature was compared to published human IPF datasets. BALB/c females were treated with AdIL-6 in combination with Bleo (AdIL-6+Bleo) or control comparators, and underwent assessments of histopathology (ECM, α-SMA accumulation), collagen content and lung physiology (Elastance, EST). Flow cytometry was used to characterize T cell and Macrophage subsets, and T cell depletion studies (anti-CD4/CD8) were completed to assess T cells role in fibrosis. Bulk RNA sequencing generated gene signatures were compared to that of other rodent fibrosis models and published human datasets of IPF datasets. The AdIL-6+Bleo treatment resulted in robust fibrosis measures (day21), sustained fibrosis until at least day 50, a unique cytokine profile at day 7, and increased activated CD4+Tcells, CD8+Tcells, and CD16+MHChi/Clec7a/iNOS-/Arg1-/CD206- macrophages. T cell depletion markedly decreased fi-brotic responses and this population of macrophages. The Day 21 AdIL-6+Bleo transcriptome shared more genes with each of two human IPF datasets than Bleo alone in C57Bl/6 mice or other rodent models. We conclude that AdIL-6+Bleo in BALB/c mice offers a superior preclinical model for studying IPF mechanisms and potential therapeutic intervention.
Wnt signaling plays central roles in embryogenesis/development, skeletal homeostasis, tumour development, and other diseases. The pathway is initiated by Wnt ligands which can be bound and inhibited by sFRP1. Regulation of sFRP1 in lung inflammation needs increased study, and little is known about which cytokines can induce sFRP1, nor the role of gp130 cytokines in its modulation. Here we used AdOSM (Advector expressing mouse Oncostatin M [OSM]) administration to overexpress the gp130 cytokine OSM in mice in vivo, and applied Nanostring, RT-PCR, and immunoblots to measure mRNA and protein levels. OSM induced robust increases in mRNA for sFRP-1 in context of reduced Wnt ligand and receptor mRNA (Wnt10B, Wnt3A, Wnt2, Wnt11, LRP5 and LRP6). Axin-2 mRNA, as a b-catenin target gene, was also suppressed suggesting an inhibition of Wnt signaling pathways. AdOSM could induce sFRP1 in IL-6KO mice, while overexpression of IL-6 (AdIL-6 vector) did not. Immunoblots of total lung extracts showed increases in the 35Kd sFRP1 protein species. In situ hybridization of mouse lung histological sections using specific sFRP1 probes showed staining in the subepithelial layer of the airways, consistent with fibroblast or myofibroblast locations in lung mucosa. In vitro, recombinant OSM stimulated sFRP1 mRNA in cultures of mouse lung fibroblasts and NIH-3T3 cells. The results support the novel observation that OSM can induce sFRP1 in vitro and in vivo, and suggest this axis contributes to the control of Wnt signaling pathways in lung inflammation.